This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Alhazzani W, Møller MH, Arabi YM et al (2019) Surviving sepsis campaign: guidelines on the management of critically ill adults with coronavirus disease 2019 (COVID-19). Crit Care Med.
ARDS Definition Task Force, Ranieri VM, Rubenfeld GD, Thompson BT et al (2012) Acute respiratory distress syndrome: the Berlin Definition. JAMA. 307(23):2526–2533
Cai Q, Yang M, Liu D et al (2020) Experimental treatment with favipiravir for COVID-19: an open-label control study. Engineering (Beijing). https://doi.org/10.1016/j.eng.2020.03.007
Ding L, Wang L, Ma W et al (2020) Efficacy and safety of early prone positioning combined with HFNC or NIV in moderate to severe ARDS: a multi-center prospective cohort study. Crit Care 24:28
Gautret P, Lagier JC, Parola P et al (2020) Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020:105949
Grasselli G, Zangrillo A, Zanella A et al (2020) Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy Region, Italy. JAMA. 323(16):1574–1581
Guan WJ, Ni ZY, Hu Y et al (2020) Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. published online Feb 28
Huang BH, Wu CH, Hsia CP, Yin Chen C (2007) Azithromycin-induced torsade de pointes. Pacing Clin Electrophysiol 30:1579–1582
Huang C, Wang Y, Li X et al (2020) Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 395(10223):497–506
Inci K (2020) Safe intrahospital transport of critically ill COVID-19 patients. J Crit Intensive Care 11(Suppl. 1):18–19
Li L, Zhang W, Hu Y et al (2020) Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: a randomized clinical trial. JAMA. https://doi.org/10.1001/jama.2020.10044
Martins IJ (2020) COVID-19 infection and anti-aging gene inactivation. Acta Scientific Nutritional Health 4(5):01–02
Mehta P, McAuley DF, Brown M et al (2020) COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 395(10229):1033–1034
Morgan ND, Patel SV, Dvorkina O (2013) Suspected hydroxychloroquine-associated QT-interval prolongation in a patient with systemic lupus erythematosus. J Clin Rheumatol 19:286–288
National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome (ARDS) Clinical Trials Network, Wiedemann HP, Wheeler AP et al (2006) Comparison of two fluid-management strategies in acute lung injury. N Engl J Med. 354(24):2564–2575
Pan C, Chen L, Lu C et al (2020) Lung recruitability in COVID-19-associated acute respiratory distress syndrome: a single-center observational study. Am J Respir Crit Care Med. 201(10):1294–1297
Peng QY, Wang XT, Zhang LN (2020) Chinese Critical Care Ultrasound Study Group (CCUSG). Findings of lung ultrasonography of novel coronavirus pneumonia during the 2019–2020 epidemic. Intensive Care Med. 46(5):849–850
Phua J, Weng L, Ling L et al (2020) Intensive care management of coronavirus disease 2019 (COVID-19): challenges and recommendations. Lancet Respir Med. 8(5):506–517
Ranucci M, Ballotta A, Di Dedda U et al (2020) The procoagulant pattern of patients with COVID-19 acute respiratory distress syndrome. J Thromb Haemost. https://doi.org/10.1111/jth.14854
Richardson S, Hirsch JS, Narasimhan M et al (2020) Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. JAMA. 323(20):2052–2059
Schünemann HJ, Khabsa J, Solo K et al (2020) Ventilation techniques and risk for transmission of coronavirus disease, including COVID-19: a living systematic review of multiple streams of evidence. Ann Intern Med 173(3):204–216. https://doi.org/10.7326/M20-2306
Sud S, Friedrich JO, Taccone P et al (2010) Prone ventilation reduces mortality in patients with acute respiratory failure and severe hypoxemia: systematic review and meta-analysis. Intensive Care Med. 36(4):585–599
Wang D, Hu B, Hu C et al (2020a) Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan, China. JAMA. 323(11):1061–1069
Wang M, Cao R, Zhang L et al (2020b) Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 30(3):269–271
Wu Z, McGoogan JM (2020) Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 Cases from the Chinese Center for Disease Control and Prevention. JAMA. https://doi.org/10.1001/jama.2020.2648
Yang X, Yu Y, Xu J et al (2020) Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med. 8(5):475–481
Yao X, Ye F, Zhang M et al (2020) Vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin Infect Dis:ciaa237
Zhou F, Yu T, Du R et al (2020) Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 395(10229):1054–1062
Acknowledgment
The authors thank all the healthcare professionals who died during the fight against the corona pandemic worldwide.
Funding
This work was not supported financially by any institution or organization.
Conflict of Interest
The authors declare that they have no conflict of interest.
Ethical Approval
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee (Ethical Committees of the Yıldırım Beyazıt University) and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2021 The Author(s), under exclusive license to Springer Nature Switzerland AG
About this chapter
Cite this chapter
Ağababaoğlu, İ., İnci, K. (2021). Management of COVID-19 in the Intensive Care Unit. In: Asea, A.A.A., Kaur, P. (eds) Coronavirus Therapeutics – Volume II. Advances in Experimental Medicine and Biology, vol 1353. Springer, Cham. https://doi.org/10.1007/978-3-030-85113-2_5
Download citation
DOI: https://doi.org/10.1007/978-3-030-85113-2_5
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-85112-5
Online ISBN: 978-3-030-85113-2
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)